Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2022 Earnings Conference Call November 28, 2022 4:30 PM ET

Company Participants

Vincent Anzalone - VP, IR

Christopher Anzalone - President and CEO

Javier San Martin - Chief Medical Officer

James Hamilton - SVP, Discovery and Translational Medicine

Ken Myszkowski - CFO

Tracie Oliver - Chief Commercial Officer

Patrick O'Brien - Chief Operating Officer & General Counsel

Conference Call Participants

Maury Raycroft - Jefferies

Luca Issi - RBC Capital Markets

Ellie Merle - UBS

Joel Beatty - Robert W. Baird

Edward Tenthoff - Piper Sandler

Patrick Trucchio - H.C. Wainwright

Madhu Kumar - Goldman Sachs

Mayank Mamtani - B. Riley Securities

Keay Nakae - Chardan Capital Markets

Mani Foroohar - SVB Securities

Operator

Ladies and gentlemen, welcome to Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode. After the presentation, there will be opportunity to ask questions.

I will now hand the conference over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.

Vincent Anzalone

Thank you, Justin. Good afternoon, everyone, and thank you for joining us today to discuss Arrowhead's results for its fiscal 2022 fiscal year ended December 30, 2022. With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, our Chief Medical Officer, who will provide an update on our mid- and later-stage clinical pipeline; Dr. James Hamilton, our Senior Vice President of Discovery and Translational Medicine, who will provide an update on our earlier stage programs; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials. In addition, Tracie Oliver, our Chief Commercial Officer; and Patrick O'Brien, our Chief Operating Officer and General Counsel, will both be available during the Q&A portion of the call.

Before we begin, I would like to remind you that comments made during today's call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements.

For further details concerning these risks and uncertainties, please refer to our SEC filings including our most recent annual report on Form 10-K and our quarterly reports on Form 10-Q.